Table 3.
Standardized Differences (%) Before and After Propensity Matching in Men
| Dabigatran vs Rivaroxaban | Dabigatran vs Warfarin | Rivaroxaban vs Warfarin | ||||
|---|---|---|---|---|---|---|
| Pre‐Matching | Post‐Matching | Pre‐Matching | Post‐Matching | Pre‐Matching | Post‐Matching | |
| Demographics | ||||||
| Age | −3.28% | −2.56% | −34.02% | 2.02% | −30.71% | 4.38% |
| Race | ||||||
| White | −1.07% | −1.59% | 12.25% | −2.53% | 13.31% | −1.10% |
| Black | 0.61% | 0.08% | −10.01% | 0.50% | −10.60% | 0.44% |
| Other | 0.85% | 1.82% | −7.47% | 2.69% | −8.32% | −0.11% |
| Comorbid conditions | ||||||
| Heart failure | 0.29% | 0.81% | −28.98% | 0.12% | −29.28% | −0.64% |
| Cardiomyopathy | −2.04% | −1.22% | −12.12% | 0.78% | −10.09% | 1.89% |
| Peripheral vascular disease | −1.55% | −0.20% | −17.27% | 0.76% | −15.72% | 0.94% |
| Hypertension | −2.48% | 0.46% | −5.28% | −0.43% | −2.81% | −0.91% |
| Diabetes mellitus | −0.37% | 0.58% | −12.30% | −0.05% | −11.94% | −0.62% |
| Renal disease | 3.45% | −1.74% | −38.94% | −0.61% | −42.29% | 0.76% |
| Liver disease | −1.20% | 2.74% | −5.61% | 1.49% | −4.42% | −1.09% |
| Previous stroke or transient ischemic attack | −0.87% | −1.33% | −14.55% | −3.79% | −13.68% | −2.55% |
| Previous myocardial infarction | −0.91% | −0.80% | −18.30% | −1.59% | −17.39% | −0.87% |
| Other arrhythmia | −1.15% | −0.59% | −8.91% | −0.50% | −7.76% | 0.08% |
| Cardiac device | −5.03% | −1.56% | −12.03% | 0.40% | −7.03% | 1.80% |
| Previous major bleeding | ||||||
| Intracranial hemorrhage | 0.36% | −1.03% | −5.41% | 0.01% | −5.75% | 0.84% |
| Gastrointestinal hemorrhage | 0.59% | −0.50% | −5.93% | −0.68% | −6.52% | −0.18% |
| Comorbidity scores | ||||||
| Gagne Score | −0.80% | 0.29% | −47.13% | −0.71% | −46.17% | −0.95% |
| CHA2DS2‐Vasc Score | −3.88% | −1.25% | −34.89% | −2.63% | −31.15% | −1.42% |
| HAS‐BLED Score | −0.10% | 0.62% | −30.32% | −0.17% | −30.25% | −0.74% |
| Previous healthcare services | ||||||
| Inpatient hospital days | 0.36% | 0.56% | −36.13% | −1.94% | −36.09% | −2.31% |
| Number unique prescription ingredients | −0.76% | 2.91% | −12.45% | 1.69% | −11.75% | −1.10% |
| Previous extended care or skilled nursing stay | 1.75% | −0.17% | −19.75% | −0.25% | −21.35% | −0.13% |
| Medications in the prior 90 days | ||||||
| Statin | −1.91% | 1.82% | 3.65% | −0.66% | 5.56% | −2.48% |
| Prescription antiplatelet | −2.09% | 0.93% | −8.90% | 1.36% | −6.83% | 0.48% |
| Proton pump inhibitors | −1.29% | 0.72% | −2.60% | −0.48% | −1.31% | −1.19% |
| NSAID | 0.25% | 1.34% | 4.25% | 1.46% | 4.00% | 0.09% |
CHA2DS2‐VASc indicates 1 point each for congestive heart failure diagnosis, female sex, hypertension diagnosis, diabetes mellitus diagnosis, age 65 to 75 years, and vascular disease diagnosis; 2 points each for age >75 years and prior stroke or transient ischemic attack; HAS‐BLED, 1 point each for hypertension diagnosis, renal disease, liver disease, stroke history, prior major bleeding, labile international normalized ratio, age >65 years, medication use predisposing to bleeding and alcohol or drug use history; NSAID, nonsteroidal anti‐inflammatory drugs.